Pharmaceutical company Mylan recently spurred a flurry of outrage after raising the price of their lifesaving EpiPen by 400%, leading many to decry “corporate greed” and point the finger at capitalism.
Unfortunately, such anger routinely fails to consider the systemic reasons as to why Mylan can charge such prices, resorting instead to knee-jerk calls for fresh tricks by the FDA and new layers of price-fixing tomfoolery from Washington.
Read more on Angry about high-priced EpiPens? Blame cronyism and overregulation…
The post Angry about high-priced EpiPens? Blame cronyism and overregulation appeared first on Acton Institute PowerBlog.
The Moral Crisis of Cronyism and Corporate Welfare